There are currently 980 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
REFLECTION: A Clinical Practice Learning Program for Galleri®
NCT05205967
Recruiting
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/17/2024
Locations: James A. Haley Veterans Hospital (VA Tampa), Tampa, Florida
Conditions: Early Detection of Cancer, Cancer
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: GCP Clinical Research, LLC, Tampa, Florida +2 locations
Conditions: Ulcerative Colitis
Register for Updates
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719
Recruiting
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: USF Health Morsani Center For Advanced Healthcare, Tampa, Florida
Conditions: Hemophilia A, Hemophilia B
Register for Updates
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178
Recruiting
This is an observational data registry study of all pediatric cancer patients at Atrium Health (AH) and participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Gender:
All
Ages:
All
Trial Updated:
05/16/2024
Locations: St. Joseph's Children's Hospital, Tampa, Florida
Conditions: Pediatric Cancer
Register for Updates
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188
Recruiting
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function
NCT06340347
Recruiting
The purpose of this study is to understand how Osivelotor is processed in people with loss of liver function. This study is seeking participants that are: stable loss of liver function with mild or moderate severity none of underlying conditions possibly affecting the study medicine being absorbed by the body All participants will receive one amount of Osivelotor by mouth before breakfast on the first day at the study clinic. A number of blood samples will be collected to understand how Osive... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Genesis Clinical Research, LLC, Tampa, Florida +1 locations
Conditions: Liver Diseases
Register for Updates
Life's End Benefits of Cannabidiol and Tetrahydrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
05/16/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Agitation, Dementia
Register for Updates
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
NCT06423950
Recruiting
To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.
Gender:
All
Ages:
All
Trial Updated:
05/16/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pediatric Cancer
Register for Updates
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330
Recruiting
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
NCT05445323
Recruiting
This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
05/16/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Friedreich Ataxia, Cardiomyopathy, Secondary
Register for Updates
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
NCT06423963
Recruiting
The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216
Recruiting
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at up to approximately 100 sites.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Tampa General Hospital (TGH) - The Stroke Center, Tampa, Florida
Conditions: Acute Stroke, Ischemic Stroke, Stroke
Register for Updates